Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on UroGen Pharma (NASDAQ:URGN) and raises the price target from $32 to $40.
June 14, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on UroGen Pharma and raises the price target from $32 to $40.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to boost investor confidence in UroGen Pharma, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100